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hy Should We Care About CARE-HF?
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ichmond, Virginia; and Magdeburg, Germany
Previous trials of cardiac resynchronization therapy (CRT) have suggested that this therapy
can significantly improve functional class and exercise capacity during short-term follow-up.
The impact of this therapy on morbidity and mortality has only recently been reported. The
Cardiac Resynchronization-Heart Failure (CARE-HF) study has definitively shown that
CRT significantly reduces mortality (36%, p  0.002) in patients with NYHA functional
class III and IV heart failure and ventricular dyssynchrony. This study also shows that CRT
reverses ventricular remodeling and improves myocardial performance progressively for at
least 18 months. In heart failure patients, the CARE-HF and Comparison of Medical
Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) (the earlier major
morbidity/mortality trial) studies together show the unequivocal benefit for CRT therapy
and CRT therapy with back-up defibrillation to significantly reduce mortality and hospital-
ization compared with optimal medical therapy. Both studies suggest the benefit of adding
the implantable cardiac defibrillator to CRT devices, as over one-third of deaths in the
CRT-pacemaker arm of both the COMPANION and CARE-HF studies were
sudden. (J Am Coll Cardiol 2005;46:2199–203) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.07.057Cardiology Foundation
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the Cardiac Resynchronization-Heart Failure (CARE-
F) trial (1) is the latest in a series of prospective random-
zed clinical trials that evaluate the benefits of cardiac
esynchronization therapy (CRT). Early trials dating back
ore than a decade have shown significant improvement in
ew York Heart Association (NYHA) functional class,
xercise time, quality of life, and oxygen consumption
uring metabolic testing (2–11). These early trials followed
atients for up to six months in a blinded fashion. Non-
nvasive cardiac testing showed an increase in ejection
raction as well as a decrease in left ventricular end diastolic
nd end systolic volumes. These early trials enrolled an
nsufficient number of patients to look at hard clinical end
oints, including total mortality, cardiovascular mortality,
nd hospitalization. A meta-analysis suggested a benefit of
RT therapy with respect to mortality and hospitalization
12).
In March 2005, the results of the CARE-HF trial were
resented at the American College of Cardiology by
r. John Cleland on behalf the CARE-HF study investi-
ators (1). This is an important trial that adds significantly
o our knowledge about the effects of CRT therapy. As a
tarting point, we wish to recognize several “firsts” accom-
lished by the CARE-HF study: 1) the first study to show
benefit for CRT pacemaker (CRT-P) alone with respect
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ccepted July 18, 2005.o survival as a single end point; 2) the first study to show a
enefit for CRT-P for up to 18 months, and continued
mprovement over time; 3) the first study to show that
eurohormonal measures (e.g., N-terminal pro-brain natri-
retic peptide) improve dramatically with CRT, and 4) the
rst study to use direct measures of dyssynchrony as an
nclusion criteria. At the same time, it is important and
omforting to us, who have begun using CRT therapy
outinely for appropriately selected patients, to see that the
esults of the CARE-HF study are entirely consistent with
hose of other major trials. The benefits of CRT shown in
he CARE-HF study with regard to improved functional
lass, improved ventricular function, improved quality of
ife, and reduced mitral regurgitation have now been estab-
ished by so many previous CRT trials that we will focus our
ttention almost entirely on the reduction in mortality and
orbidity, which were the primary end points of this trial.
ere the major contribution to cardiovascular science of the
ARE-HF study is the reinforcement and extension of the
esults from the Comparison of Medical Therapy, Pacing,
nd Defibrillation in Heart Failure (COMPANION) trial
13). The COMPANION trial randomized 1,520 patients
ith NYHA functional class III to IV congestive heart
ailure (just as in the CARE-HF study) to optimal phar-
acologic therapy (OPT) versus OPT plus CRT-P (biven-
ricular pacing alone) versus CRT-D (biventricular pacing
lus back-up defibrillation by implantable cardiac defibril-
ator [ICD]). The COMPANION trial showed a 20%
eduction (p  0.01) in the combined end point of hospi-
alization and mortality for both CRT and CRT-D, com-
ared with OPT, and showed that CRT-D reduced all-
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Care About CARE-HF Decmber 20, 2005:2199–203ause mortality by 36% (p  0.003) with respect to OPT.
ecause the COMPANION trial was not designed and
owered to be able to show mortality reduction with
RT-P alone, and its results only showed a trend toward
ortality reduction with CRT-P (hazard ratio, 0.76; p 
.059), uncertainty remained regarding whether CRT-P did
ndeed reduce mortality, and that question has now been
nequivocally resolved by the CARE-HF study.
Another important message from the CARE-HF study is
he reassuring finding that the advantages of CRT therapy,
is-a-vis best medical management, continue to increase
ver time, at least through 18 months. This information is
ver and above what we learned from the COMPANION
rial, because that trial had too few patients in follow-up
ast 12 months to be able to conclude anything beyond one
ear. The follow-up was shorter in the COMPANION trial
han in the CARE-HF study because the COMPANION
rial was stopped by the data and safety monitoring com-
ittee when the number of primary end points was
chieved. This occurred relatively early in follow-up because
he patients had much more advanced heart failure and left
entricular dysfunction in the COMPANION trial than in
he CARE-HF study. The control group mortality at 12
onths in the CARE-HF study was 12.6%, and in the
OMPANION trial was 19%. The combined incidence of
ospitalization for congestive heat failure plus mortality is
lmost two times higher in the COMPANION trial than it
as in the CARE-HF study. Most importantly, this is the
rst large trial to show a benefit in a biomarker with CRT
herapy (e.g., a surrogate measure of congestive heart failure
everity). Prior large studies have failed to show improve-
ents in neurohormonal measures, including epinephrine,
orepinephrine, dopamine, endothelin, and brain natri-
retic peptide levels. The reason that prior trials failed to
how a consistent improvement in biomarkers with CRT
herapy may be partially explained by small sample size or
nadequate follow-up. What is interesting about the
Abbreviations and Acronyms
CARE-HF  Cardiac Resynchronization-Heart
Failure study
COMPANION  Comparison of Medical Therapy,
Pacing, and Defibrillation in Heart
Failure study
CRT  cardiac resynchronization therapy
CRT-D  cardiac resynchronization therapy
pacemaker plus back-up defibrillation
(implantable cardiac defibrillator)
CRT-P  cardiac resynchronization therapy
pacemaker
ICD  implantable cardiac defibrillator
MERIT-HF  Metoprolol Randomized Intervention
Trial in Congestive Heart Failure
NYHA  New York Heart Association
OPT  optimal pharmacologic therapyARE-HF study is that there was a non-significant de- trease in N-terminal pro-brain natriuretic peptide at three
onths that was dramatically lowered by over 1,100 pg/ml
t 18 months. This change should be dramatic enough to
onvince even the biggest skeptics of CRT therapy.
Clearly, one of the most important contributions of the
ARE-HF study is that it has answered the question of
hether CRT-P reduces mortality. It does. A thorough
nalysis of the CARE-HF study and the COMPANION
rial together shows that we now understand better the
eaning of add-on therapies (in terms of CRT-D therapy,
dding defibrillation). The modern management of heart
ailure began with randomized clinical trials showing the
alue of first adding angiotensin-converting enzyme inhib-
tors to the then standard medical therapy for heart failure
e.g., diuretics and digoxin), which reduced mortality by
5% to 31% (14,15). Next a large number of studies showed
he value of adding beta-blockers to angiotensin-converting
nzyme inhibitors, achieving an additional approximately
3% reduction in mortality (16–18). The CARE-HF study,
nd the COMPANION trial, as well as virtually every CRT
rial, added CRT on top of OPT medical therapy, now also
ncluding aldosterone antagonists. The CARE-HF study
hows that CRT on top of medical therapy (70% with
eta-blockers, 95% with angiotensin-converting enzyme or
ngiotensin receptor blocker inhibitors, and 50% with aldo-
terone inhibitors) will further reduce mortality by approx-
mately one-third. The COMPANION trial, on the other
and, showed that the inclusion of an ICD integrated
ithin the CRT system—CRT-D—substantially decreases
he non-negligible sudden death mortality that remains,
espite OPT and CRT-P.
There is a note of caution that we feel obliged to
mphasize with regard to interpretation and clinical impli-
ations of the CARE-HF study. Based on the fact that the
elative mortality reduction with CRT alone in the
ARE-HF study was approximately the same as with
RT-D in the COMPANION trial, some people may
nfer that a CRT-P alone suffices. That would be an
ncorrect understanding of the key findings of the two
tudies: one-third of the deaths that occurred in the
ARE-HF study were sudden. A back-up defibrillator, i.e.,
RT-D, would have prevented many of these sudden
eaths. Figure 1 shows the percentage of deaths that were
udden in these two studies. In the COMPANION trial,
6% of the deaths in the CRT-P arm were sudden, very
imilar to the 35% in the CARE-HF study. In the absence
f ICD back-up, both studies showed that despite the
vident benefits of CRT-P therapy, one-third of the fatal-
ties were attributable to sudden death. As seen in Figure 1,
he CRT-D arm of the COMPANION trial reduced the
udden cardiac death incidence to 16%, a 55% relative risk
eduction for sudden cardiac death. In terms of absolute
ortality, 7% of patients in the CRT arm of the CARE-HF
tudy died suddenly, compared with only 2.9% in the
RT-D arm of the COMPANION trial. A comparison ofhe cost effectiveness of CRT-P with CRT-D has not yet
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Decmber 20, 2005:2199–203 Care About CARE-HFeen performed, but has important implications in countries
ith limited health care budgets. It is highly unlikely,
owever, that future trials will be done in this population
omparing patients with CRT-P and CRT-D devices to
etter quantitate the improvement in sudden cardiac death
ecause of ethical concerns and difficulty with patient
nrollment. Finally, one cannot exclude the possibility that
ong-term CRT-P therapy may reduce the incidence of
udden cardiac death by slowing the progression of conges-
ive heart failure, improving the autonomic milieu, and
ausing anatomic remodeling.
Therefore, it becomes clear that the CARE-HF study
onfirms and reinforces the message of the COMPANION
rial, namely that: 1) CRT alone confers a mortality benefit:
strong trend is seen in the COMPANION trial, hazard
atio, 0.76; p  0.059; a significant trend is seen in the
ARE-HF study, hazard ratio, 0.66; p 0.002. 2) Therapy
ith CRT-D adds substantial survival benefit, attributable
o reduction of sudden death, the COMPANION trial:
azard ratio, 0.64; p  0.01.
Finally it is worth pointing out that some of the minor
ifferences between the CARE-HF study and the COM-
ANION trial can be explained by the different patient
opulations included in the two studies as summarized in
able 1. The differing populations probably explain the
ifferent risks for mortality. The most important differences
re that: 1) only 38% of the patients in the CARE-HF study
ad coronary artery disease, compared with 56% in the
OMPANION trial; 2) the mean left ventricular ejection
raction was 25% in the CARE-HF study, compared with
1% in the COMPANION trial; and 3) a higher percentage
f the patients in the COMPANION trial were in NYHA
unctional class IV (16% vs. 6.5%). Thus, clearly the patients
n the COMPANION trial represent a cohort at higher risk
f heart failure and arrhythmic death than those in the
ARE-HF study, and this point is confirmed by the
ignificantly higher control group mortality: at one year,
9% in the COMPANION trial and 12.6% in the
igure 1. Comparison of percentage of mortality attributable to sudden
ardiac death in Comparison of Medical Therapy, Pacing, and Defibrilla-
ion in Heart Failure (COMPANION) trial and in Cardiac
esynchronization-Heart Failure (CARE-HF) study. Open bars  the
OMPANION trial; solid bars  the CARE-HF study. CRT-D 
ardiac resynchronization therapy pacemaker plus back-up defibrillation
implantable cardiac defibrillator); CRT-P  cardiac resynchronization
herapy pacemaker.ARE-HF study. The far fewer patients with coronary
f
ortery disease etiology in the CARE-HF study also warrants
omment. Based on the results of multiple ICD studies in
atients with chronic ischemic disease (19–23), some of the
otential candidates for the CARE-HF study were consid-
red candidates for ICDs, and therefore were excluded from
he CARE-HF study. In fact, the message of another
mportant recently reported large clinical trial is that pa-
ients with NYHA functional class II or III heart failure and
low ejection fraction have better survival when an ICD is
mplanted (23). This observation reinforces our earlier
omment that in a population with advanced heart failure,
uch as that studied in both the CARE-HF study and the
OMPANION trial, the risk of sudden death remains
ubstantial, thus the necessity for considering ICD for
ack-up in many of these patients.
Actually, the strategy of add-on therapies, illustrated
chematically in Figure 2, has been commonplace in treating
eart failure patients. Now, the COMPANION trial and
he CARE-HF study have shown CRT (and CRT-D) as
he next “new molecule,” providing a further one-third
ncremental protection against all-cause mortality and sud-
en death mortality over and above optimal medical ther-
py. Thus, with regard to the very specific question of using
RT-P alone or CRT-D, the question (thanks to the
igure 2. Add-on therapy in heart failure. Each added therapy incremen-
ally decreases mortality when added on top of previous therapy. See text
able 1. Patient Characteristics of Patients Enrolled
n CARE-HF and in COMPANION
CARE-HF COMPANION
OPT CRT-P OPT CRT-P
ge (yrs) 66 67 68 67
ale (%) 73 74 69 67
YHA IV (%) 7 6 18 13
RS (ms) 160 160 158 160
F (%) 25 25 22 20
AD (%) 35 41 59 54
AD  coronary artery disease; CARE-HF  Cardiac Resynchronization–Heart
ailure; COMPANION  Comparison of Medical Therapy, Pacing, and Defibril-
ation in Heart Failure; CRT-P  cardiac resynchronization pacemaker; EF  left
entricular ejection fraction; NYHA  New York Heart Association functional class;
PT  optimal pharmacologic therapy; QRS  width of QRS.or explanation and references. ACE-Inh  acetylcholinesterase inhibitor;
ther abbreviations as in Figure 1.
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Care About CARE-HF Decmber 20, 2005:2199–203ARE-HF study) is not whether CRT-P saves lives, but
hether substantially more lives may be saved by combining
RT therapy with an ICD. These results should not
urprise us. The MERIT-HF trial has shown that the
egree of sudden death risk is higher in patients with less
evere heart failure than in those with very advanced heart
ailure (18). There has been no evidence showing that CRT
lone reduces the arrhythmic risk (11). The data from the
ARE-HF study do not refute this point because the
ncidence of sudden death in the CRT arm is nearly
dentical to that in the control arm: 35% versus 32%,
espectively. Thus, because CRT improves functional class,
t is likely that the relative risk for sudden death remains
levated and provides a rationale for ICDs as an excellent
omplement to CRT therapy. These results are further
onfirmed by two single-center non-randomized series that
ave shown significant mortality reductions with CRT-D
ompared with CRT-P, very similar to the difference we
ave highlighted earlier (24–25).
It has been noted that 20% to 30% of patients who receive
RT therapy show no measurable clinical benefit. One
xplanation for this finding is that patients are selected for
RT therapy on the basis of the electrocardiogram dura-
ion, which is an imperfect measure of ventricular dyssyn-
hrony. This is the first large clinical trial to select patients
n the basis of the presence of either a very wide QRS (e.g.,
149 ms, and most of these patients are thought to have
yssynchrony) or a QRS interval between 120 and 149 ms
nd the presence of two of three additional criteria for
yssynchrony. It is likely that the selection of patients for
RT therapy using measures of dyssynchrony serves to
etter identify candidates for CRT therapy and may in-
rease the response rate and improve the outcome for
atients receiving CRT.
In conclusion, the CARE-HF study and the COMPAN-
ON trial together show unequivocal benefit for CRT in
YHA functional class III and IV congestive heart failure
ith QRS 150 ms or QRS 120 ms plus dyssynchrony.
he CARE-HF study trial showed ventricular remodeling
nd improved myocardial performance, which continued up
o at least 18 months. Both studies confirm the need of
dding the ICD to CRT devices, because more than
ne-third of deaths in the CRT-alone arm of both the
OMPANION trial and the CARE-HF study were
udden. The implications of these results for the care of
atients with moderate to severe heart failure should be
mmediately translated into clinical practice. Future re-
earch in CRT therapy will focus on patients with less
evere degrees of heart failure. We can only eagerly
nticipate these results in the coming years.
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